Cancer clinical trials in the region Pays de la Loire

439 currently recruiting clinical trials
Region Pays de la Loire
Phase 2 Lung cancer #NCT05498428 #2023-505065-91-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Janssen
Phase 2 Colon cancer #NCT06681038 #2024-514560-10-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSI/dMMR
5 recruiting sites
Institut de Cancérologie de l'Ouest
Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT04428554
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
14 recruiting sites
Institut Claudius Regaud
Phase 2 Breast cancer #NCT04666961
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRCA 1/2
7 recruiting sites
Institut de Cancérologie de l'Ouest
Phase 2 Lung cancer #NCT05718323
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
ETOP IBCSG Partners Foundation
Phase 2 Lymphoma #NCT04920617
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Indolent transformed lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
ImmunoVaccine Technologies, Inc.
Phase 2 Kidney cancer #NCT04299646
Required histologic types
Clear cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required IMDC scores
0 1 or 2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Targeted therapy
9 recruiting sites
Centre François Baclesse
Phase 1 / Phase 2 Breast cancer #NCT04585750 #2023-504251-27-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
Other KRAS KRAS G12C KRAS G12D KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT04585750 #2023-504251-27-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
Other KRAS KRAS G12C KRAS G12D KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Endometrial cancer #NCT04585750 #2023-504251-27-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
Other KRAS KRAS G12C KRAS G12D KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc